Breast Cancer Clinical Trials

Country Sites

BIG 1-98 Trial — The BIG 1-98 trial is a multinational, phase 3, randomized, double-blind, clinical trial conducted in more than 8,000 patients the largest study of an aromatase inhibitor (AI) as up-front adjuvant therapy for early breast cancer^3,4. Learn more

MA-17 Trial — Landmark MA-17 trial is the first study to prove the benefit of extended adjuvant therapy in postmenopausal women after standard adjuvant tamoxifen.
Learn more

Clinical Trial in First-Line Treatment of Advanced Breast Cancer — The first-line study (Mouridsen, et al, Superior efficacy of letrozole (FEMARA^®) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group) is available as Web pages or in PDF format. The abstract is also available in PDF format. Learn more

DISCLAIMER: This is an international website for FEMARA® (letrozole) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the For U.S. Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.